Does Strattera Increase Dopamine?
Yes, atomoxetine (Strattera) does increase dopamine, but only selectively in the prefrontal cortex—not in other brain regions like the striatum or nucleus accumbens. This regional specificity is a key distinguishing feature from stimulant medications and explains why atomoxetine lacks abuse potential and motoric side effects 1.
Mechanism of Action
Atomoxetine is classified as a selective norepinephrine reuptake inhibitor. It increases synaptic noradrenaline by binding to the norepinephrine transporter throughout the brain. However, in the prefrontal cortex specifically, norepinephrine transporters are also responsible for dopamine reuptake because dopamine transporters are scarce in this region. Consequently, atomoxetine increases both noradrenaline and dopamine in the synapses within the prefrontal cortex 1.
Quantifying the Dopamine Increase
The magnitude of dopamine elevation has been measured in preclinical studies:
- In the prefrontal cortex, atomoxetine increases extracellular dopamine concentrations approximately 3-fold 2
- This effect is region-specific: atomoxetine does not alter dopamine levels in the striatum or nucleus accumbens 2, 3
- The norepinephrine increase is more widespread, occurring robustly throughout the brain including prefrontal cortex, occipital cortex, lateral hypothalamus, dorsal hippocampus, and cerebellum 3
Clinical Context of These Findings
In contrast, methylphenidate (a stimulant) increases dopamine equally in the prefrontal cortex but also significantly elevates dopamine in the striatum and nucleus accumbens 2. This regional selectivity of atomoxetine—increasing dopamine only in the prefrontal cortex—is hypothesized to mediate its therapeutic effects in ADHD while avoiding the motoric effects and abuse liability associated with striatal and nucleus accumbens dopamine elevation 2.
Important Clinical Considerations
Effect Size and Onset
- Atomoxetine has medium effect sizes for ADHD symptom reduction, generally smaller than stimulants 1
- Treatment effects are not observed until 6-12 weeks after initiation, unlike stimulants which have rapid onset 1
- Current guidelines recommend atomoxetine as second-line treatment, with stimulants as first-line 1
When Atomoxetine May Be Preferred First-Line
Atomoxetine should be considered as a first-line option in patients with:
- Substance use disorders (where stimulants may be unviable due to their dopaminergic activity in nucleus accumbens and striatum) 1
- Disruptive behavior disorders
- Tic disorder or Tourette's syndrome
- Comorbid anxiety or autism spectrum disorder 1
Dosing Considerations
The standard dosing follows a weight-based approach:
- Children/adolescents ≤70 kg: Start at 0.5 mg/kg/day, target 1.2 mg/kg/day (maximum 1.4 mg/kg/day or 100 mg, whichever is less) 4
- Children/adolescents >70 kg and adults: Start at 40 mg/day, target 80 mg/day (maximum 100 mg/day) 4
Critical caveat: Approximately 7% of Caucasian populations are CYP2D6 poor metabolizers with 10-fold higher drug exposure. In these patients or when using strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine), initiate at 50% of normal dose and increase cautiously 4.
Safety Monitoring
Monitor closely for: